With new phase 3 data backing the ability of its emergency use zalunfiban to fend off further heart damage, CeleCor Therapeutics is one step closer to bringing a speedy new weapon to the race against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback